Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report

Hua Duan 1
Yanmei Peng 1
Huijuan Cui 2
Yuqin Qiu 1
Qiang Li 1
Jingyi Zhang 1
Wen Shen 1
Chenyao Sun 1
Chufan Luo 1

1 Department of China–Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China;
2 Department of Oncology, China–Japan Friendship Hospital, Chaoyang, Beijing, China

Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations. A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors.

Keywords: NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), S768I, afatinib, gefitinib

Introduction
Lung cancer is the leading cause of cancer deaths according to GLOBOCAN estimates and has caused stressful burden on the society. Cancer Statistics in China revealed similar phenomenon. In recent years, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have improved the progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with sensitive mutations, compared to traditional chemotherapy (9.2–13.1 vs 4.6–6.3 months). The sensitive mutations include deletions in exon 19 or L858R mutations in exon 21, which account for 85% of all epidermal growth factor receptor (EGFR) mutations and are associated with sensitivity to EGFR-TKIs. Different generations of EGFR-TKIs showed no significant differences in sensitive mutations. Meanwhile, the incidence rates of uncommon mutation such as G719X, S768I, L861Q, and exon 20 insertion mutations are 4%–13%, and their response effects to EGFR-TKIs remain unclear.

Exon 20 p.S768I mutation is one of the uncommon mutations. Previous reports contradict on which generation has a better effect on S768I mutation. LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 studies showed that afatinib (Boehringer Ingelheim Pharmaceutical Co., Ingelheim, Germany) revealed benefits among eight patients who carried S768I mutation. However, only one case had the single S768I mutation. Here, we report a case of afatinib’s response in an advanced NSCLC female patient who failed treatment with gefitinib (AstraZeneca plc, London, UK).
Case report

In March 2013, a 52-year-old Chinese female with no smoking history had sudden coughs with bloody sputum and chest pain. Positron emission tomography-computed tomography (CT) taken in Peking Union Medical College Hospital showed a mass in the left upper lung sized 39×49 mm$^2$ and the standard uptake value was 5.8. Meanwhile, several masses sized 8 mm in the mediastinum were observed without increased radioactive uptake. On April 16, 2013, upper left lung resection and mediastinal lymph node dissection were performed. Finally, the patient was diagnosed with lung adenocarcinoma on the left upper lobe with stage IIa (pT2aN1M0), as shown in Figure 1. Molecular pathology suggested EGFR exon 20 p.S768I mutation (2303G>T). Also, in her family, her father and one uncle died of lung cancer and another uncle died of kidney cancer.

From June to October 9, 2013, the patient was treated with adjuvant chemotherapy in another hospital (pemetrexed plus cisplatin, but the dose was unknown) for four therapy circles. Chest CT scan showed no recurrence. However, on October 10, 2014, a regular chest CT scan showed a new mass with a diameter of 10 mm in the left upper lung and several new masses in the right lung with a maximum diameter of 4 mm, that is, metastasis in mediastinal 4R, 4L, six regions, and left pleural effusion.

From October 2014 to December 2016, the patient accepted four-line therapies with chemotherapies and bevacizumab. Among the treatments, the fourth line treatment maintained 15 cycles and the patient benefited the longest PFS lasting for 14 months (Table 1). On December 30, 2016, a circulating tumor DNA liquid biopsy by the Amplification Refractory Mutation System was performed. And the result was the same as the surgical specimen two years ago (Figure 2). Because afatinib was not available in China at that time, we recommended the first-generation EGFR-TKI gefitinib (250 mg/day) with bevacizumab. One month later, the chest CT scan revealed that the metastases increased widely in both lungs, indicating that gefitinib was of primary resistance (Figure 3A and B). On March 3, 2017, the patient started taking afatinib (40 mg/day) with bevacizumab. The chest CT scan revealed the metastases shrank obviously after 1 month (Figure 3C). After 3 months, the patient had two-grade diarrhea and one-grade rash on the back neck. The efficacy evaluation was partial response. Now, the patient has PFS for 6 month (Table 1).

The patient has signed written informed consent for publishing the case details and any accompanying images.

Discussion

The patient was diagnosed with left lung adenocarcinoma without sensitive EGFR mutation. The initial stage was IIa, and the margin was negative. According to the National Comprehensive Cancer Network (NCCN) Guideline,12 chemotherapy was recommended as the adjuvant therapy. After four cycles of therapy and 16-month disease-free survival, locoregional recurrence and distant metastases occurred. Chemotherapy or bevacizumab combined with chemotherapy was recommended according to the NCCN Guideline.12 According to the NCCN Guideline, bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, can be used as the first-line therapy for lung adenocarcinoma until the disease progressed.12 Many classic clinical studies13–16 also proved its efficacy in NSCLC, compared with traditional chemotherapy. The classic ECOG459916 and BEYOND13 studies have proved that bevacizumab with carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC. Table 1 shows the survival benefits from chemotherapy or bevacizumab.

When the disease progressed, the tissue samples could not be obtained due to the poor physical strength of the patient, so we performed circulating tumor DNA liquid biopsy, which was the feasible sample for EGFR mutation analysis.17,18 EGFR exon 20 S768I mutation was detected just like before. Hellmann et al19 reported a case whose mass spectrometry genotyping revealed EGFR S768I mutation among surgical specimens in 2001, 2003, and 2013, respectively. Besides, erlotinib had resulted in partial radiographic response until T790M mutation occurred.

To the best of our knowledge, this is the first case wherein a patient with S768I mutation received first- and second-generation EGFR-TKIs successively, and the response was completely different. The S768I mutation is a rare subset of

![Figure 1](image_url)
EGFR mutants located in exon 20 (incidence 1%–2%).\textsuperscript{10,20} Common mutations including exon 19 deletions and L858R in exon 21 have shown sensitivity to EGFR-TKIs, no matter which generations they are.\textsuperscript{6,7} However, the effects of uncommon EGFR mutations such as S768I mutation remain largely unknown. Although the analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6\textsuperscript{11} proved that eight patients with S768I mutation all showed partial remission with afatinib, the limitation is obvious since the sample size was small and only one patient had single S768I mutation. In addition, Kuiper et al\textsuperscript{21} and Beau-Faller et al\textsuperscript{22} discovered that the disease control rate (DCR) was better with EGFR-TKIs for complex mutations than for a single mutation. Although some cases could be explained because they carried attractive mutations such as 19 deletions or L858R in exon 21 simultaneously, most conditions remain unclear.

The female patient carried single S768I mutation according to two molecular pathologic tests. The effects of first- and second-generation EGFR-TKIs were completely different. To evaluate the effect of the single S768I mutation on the response to TKIs, we reviewed the previous cases and studies (Table 2). Table 2 shows that all the patients accepting afatinib showed partial remission or stable disease. The DCR is 100%. By contrast, the DCR of patients who accepted the first-generation TKIs such as erlotinib, gefitinib, and icotinib was 46.2%. Our case showed similar result. In addition to clinical researches, some experimental studies confirmed the value of different TKIs on S768I mutation. Tanizaki et al\textsuperscript{23} examined the sensitivity of Ba/F3 cells expressing EGFR (L858R) or EGFR (S768I) to EGFR-TKIs by calculating the median inhibitory concentration (IC\textsubscript{50}) values and a ratio relative to those for cells expressing EGFR (L858R). The result was inspiring because the IC\textsubscript{50} values of afatinib were minimal. Regarding the IC\textsubscript{50} ratios, the second-generation drugs’ ratios were much smaller than those of the first- and the third-generation drugs. Kancha et al\textsuperscript{24} and Banno et al\textsuperscript{25} carried out similar experiments and drew similar conclusions. Therefore, S768I mutation is more sensitive to the second-generation TKI (afatinib) than the first-generation TKIs (erlotinib, gefitinib, and icotinib).

Up to now, 6-month PFS was achieved from afatinib combined with bevacizumab. The NEJ002 study\textsuperscript{26} found that the median survival time of patients treated with gefitinib, platinum, and pemetrexed or docetaxel was around 3 years. Previous studies proved the benefits of EGFR-TKIs combined with anti-vascular endothelial growth factor therapy, such as bevacizumab and apatinib.\textsuperscript{27–29} Furthermore, the

**Table 1** Detailed medications and treatment

| Time periods                        | Treatment                                                                 | Line | Cycle | RECIST | PFS (month) |
|-------------------------------------|---------------------------------------------------------------------------|------|-------|--------|-------------|
| From November 2014 to January 2015  | Fosfamide 2 g days 1–3 and pemetrexed 800 mg day 4, every 21 days         | 1    | 2     | PD     | –           |
| From March 17 to April 18, 2015     | Navelbine 40 mg day 1/day 8 and carboplatin 400 mg day 2 and bevacizumab 400 mg day 1, every 21 days | 2    | 6     | PR     | 4           |
| From May 12 to July 29, 2015        | Navelbine 40 mg day 1/day 8 and oxaliplatin 150 mg day 2 and bevacizumab 400 mg day 1, every 21 days | 3    | 1     |        |             |
| From September 2 to October 19, 2015| Gemcitabine 1.8 g day 1/day 8 and bevacizumab 400 mg day 1, every 21 days | 4    | 15    | PD     | 14          |
| From November 9, 2015, to October 12, 2016 | Paclitaxel 210 mg day 1 and bevacizumab 400 mg day 1, every 21 days | 2    |       |        |             |
| From November 11 to December 7, 2016| Paclitaxel 180 mg day 1 and oxaliplatin 150 mg day 1 and bevacizumab 400 mg day 1, every 21 days | 5    | 1     | PD     | –           |
| From January 14 to February 14, 2017| Gefitinib 250 mg/day and bevacizumab 400 mg day 1, every 21 days          | 6    | 4     | PR     | 6           |

**Abbreviations:** PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, response evaluation criteria in solid tumors.
European Society for Medical Oncology recommends bevacizumab combined with erlotinib as the first-line therapy for metastatic NSCLC. Comprehensive treatment could bring benefits to advanced NSCLC patients.

T790M mutation accounted for half of the known mechanisms of resistance. Patients with single S768I mutation also acquired secondary T790M mutation. Meanwhile, another clinical case reported that patients with L858R mutation showed resistance after TKI therapy and secondary S768I mutation occurred in repeated molecular pathology. May be the occurrence of secondary S768I mutation could be the potential resistance mechanism.

**Conclusion**

Our case indicates that the second-generation TKI (afatinib) could be better than the first-generation TKI (gefitinib). Afatinib may be an effective treatment for NSCLC patients with single S768I mutation. Comprehensive treatment could

---

**Figure 3** Thoracic computed tomography (CT) before taking gefitinib (A); after taking gefitinib, metastases increased widely in both lungs (B); after taking afatinib for one month, the metastases shrank obviously (C).
bring benefits to advanced NSCLC patients. However, further clinical data are required for patients with advanced NSCLC harboring a single S768I mutation in order to provide more powerful evidences.

**Acknowledgments**
This case report was supported by China–Japan Friendship Hospital. We would like to thank Resident Huang Chen (Pathology Department, China–Japan Friendship Hospital, Beijing, China) for pathologic reading. Our thanks also go to Professor Qing Wu (English Department, School of Humanities, Beijing University of Chinese Medicine, Beijing, China) and Liang Liang (a postgraduate studying Translation Theory and Practice at Renmin University of China) for improving language quality. We also express our gratitude to the patient and her husband. HD and YP are co-first authors.

**Author contributions**
HD, HC, YP, and YQ were responsible for collection and assembly of the patient’s data. HD, YP, QL, JZ, WS, CS, and CL performed data analysis and literature searching. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65(2):87–108.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115–132.
3. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2011;12(8):735–742.
4. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13(3):239–246.
5. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol*. 2010;11(2):121–128.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004;350(21):2129–2139.
7. Pazes JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004;306(5676):1497–1500.
8. Wu T, Hsueh EH, Lee JH, Lin CC, Yang JC. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. *Expert Rev Respir Med*. 2016;10(1):31–55.
9. Improtta G, Pettinato A, Gieli S, et al. Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: a case report combined with a review of the literature and investigation of clinical significance. *Oncol Lett*. 2015;11(1):393–398.
10. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. *Cancer Sci*. 2016;107(9):1179–1186.
11. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol*. 2015;16(7):830–838.
12. Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. *J Natl Compr Canc Netw*. 2016;14(3):255–264.

**Table 2** Summary of reported clinical response to TKIs in patients harboring the single EGFR S768I mutation

| Author | Year | Nationality | Age | Sex | Smoking | Stage | EGFR-TKI | Prior therapy | Line | RECIST | PFS |
|--------|------|-------------|-----|-----|---------|-------|----------|--------------|------|--------|-----|
| Masago et al<sup>34</sup> | 2010 | Japanese | 81 | M | 37 pack-years | IV | Gefitinib | – | 2 | PR | 461 days |
| Lund-Iversen et al<sup>19</sup> | 2011 | Norwegian | 73 | F | Former | IV | Erlotinib | Chemotherapy | 2 | PD | 1 month |
| Weber et al<sup>24</sup> | 2014 | Danish | – | – | – | IV | Erlotinib | Chemotherapy | 2 | PD | 1 month |
| Hellmann et al<sup>25</sup> | 2014 | American | – | – | 5 pack-years | IV | Erlotinib | – | 1 | PR | 8 years |
| Pallan et al<sup>17</sup> | 2014 | Afro-Caribbean | 56 | M | 1 pack-year | IV | Gefitinib | – | 1 | PD | 6 weeks |
| Chiu et al<sup>38</sup> | 2015 | Taiwanese | – | – | – | IV | Gefitinib or erlotinib | – | 2PD | – |
| Heigener et al<sup>19</sup> | 2015 | German | – | – | – | IV | Afinatinib | – | – | SD | – |
| Yang et al<sup>32</sup> | 2015 | Chinese | 56 | F | – | IV | Afinatinib | – | 1 | PR | 5 months |
| Yang et al<sup>31</sup> | 2015 | Chinese | – | – | – | IV | Afinatinib | – | – | PR | – |
| Leventakos et al<sup>31</sup> | 2016 | Chinese | – | – | – | IV | Gefitinib | – | – | PD | 3 months |
| Klughammer et al<sup>31</sup> | 2016 | Chinese | – | – | – | IV | Gefitinib | – | – | PR | – |
| Cheng et al<sup>31</sup> | 2016 | Chinese | 59 | F | – | IV | G-TKI | – | – | PR | 8.6 months |
| Kobayashi et al<sup>34</sup> | 2016 | Japanese | 61 | F | – | IV | Afinatinib | – | 11 | PR | 12 months |
| Zhang et al<sup>31</sup> | 2017 | Chinese | 64 | M | – | – | Icotinib | – | 2 | SD | 31 months |
| Zhu et al<sup>31</sup> | 2017 | Chinese | 52 | F | – | IV | Gefitinib | – | 1 | SD | 8.8 months |
| Russo et al<sup>31</sup> | 2017 | Italian | 65 | M | – | IV | Afinatinib | – | 1 | PR | 3 months |

**Abbreviations:** I, first-generation; EGFR, epidermal growth factor receptor; F, female; M, male; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease; TKI, tyrosine kinase inhibitor.
28. Otsuka K, Wu Y, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204.

27. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL). Ann Oncol. 2010;21(9):1804–1809.

26. Inoue A, Kobayashi K, Maemondo M, et al; North-East Japan Study Group. Clinicopathological characteristics of 11 NSCLC patients with EGFR exon 20 mutations. J Thorac Oncol. 2012;7(9):1471–1473.

25. Schwaederle MC, Patel SP, Husain H, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017;23(17):5101–5111.

24. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential mechanisms of resistance to afatinib in a patient with lung cancer harboring two uncommon EGFR mutations. Mol Cancer Ther. 2013;12(2):220–229.

23. Tanizaki J, Banno E, Togashi Y, et al. Case report: durable response to afatinib in a patient with lung cancer harbouring two uncommon mutations of EGFR and a KRAS mutation. Lung Cancer. 2016;101:11–15.

22. Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 20 mutations in non-small-cell lung cancer on 10117 patients: outcomes following EGFR-TKI treatment. Br J Cancer. 2016;115(12):1504–1512.

21. Hellmann MD, Reva B, Yu H, et al. Clinical and in vivo evidence that EGFR S768I mutation in lung adenocarcinoma are sensitive to erlotinib. J Thorac Oncol. 2014;9(10):e73–e74.

20. Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathological characteristics. Mol Cancer Ther. 2013;12(2):220–229.

19. Hellmann MD, Reva B, Yu H, et al. Clinical and in vivo evidence that EGFR S768I mutation in lung adenocarcinoma are sensitive to erlotinib. J Thorac Oncol. 2014;9(10):e73–e74.

18. Lunn-Iversen M, Kleingarn M, Fjellbirkeland L, Helland A, Brustugun OT. Clinicopathological characteristics of 11 NSCLC patients with EGFR exon 20 mutations. J Thorac Oncol. 2012;7(9):1471–1473.

17. Weber B, Hager H, Sorensen BS, et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with nonsmall cell lung cancer. Lung Cancer. 2014;83(2):224–230.

16. Pallan L, Taniere P, Koh P. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases. J Thorac Oncol. 2014;9(10):e75–e76.

15. Cheng G, Song Z, Chen D. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 2015;10(5):793–799.

14. Heijenroder M, Schumann C, Sebastian M, et al; Afinatinib Compassionate Use Consortium (ACUC). Afinatinib in nonsmall cell lung cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitors. Oncologist. 2015;20(1):1167–1174.

13. Zhou C, Wu Y, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204.

12. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–1423.

11. Zhan C, Wu Y, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204.

10. Reck M, Wei J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–1423.

9. Zhan C, Wu Y, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204.

8. Reck M, Hagiwara K, Han B, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS Study. J Thorac Oncol. 2016;11(10):1682–1689.

7. Schwartzler MC, Patel SP, Husain H, et al. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin Cancer Res. 2017;23(17):5101–5111.

6. Hellmann MD, Reva B, Yu H, et al. Clinical and in vivo evidence that EGFR S768I mutation lung adenocarcinoma are sensitive to erlotinib. J Thorac Oncol. 2014;9(10):e73–e74.

5. Banno E, Togashi Y, Nakamura Y, et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Cancer Sci. 2016;107(8):1134–1140.

4. Inoue A, Kobayashi K, Maemondo M, et al; North-East Japan Study Group. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemotherapy-naive non-small-cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–59.

3. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244.

2. Otsuka K, Hata A, et al. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small-cell lung cancer. Cancer Chemother Pharmacol. 2015;76(4):835–841.

1. Peng Y, Cui H, Liu Z, et al. Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. Onco Targets Ther. 2017;10:2289–2295.
Afatinib in advanced NSCLC with single EGFR exon 20 S768I mutation